Calithera Biosciences, Inc. (NASDAQ:CALA – Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.00 and traded as high as $0.0003. Calithera Biosciences shares last traded at $0.0003, with a volume of 1,200 shares trading hands.
Calithera Biosciences Stock Performance
The firm has a market capitalization of $1,158.00, a price-to-earnings ratio of -0.00 and a beta of -1.32.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies.
The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity.
Read More
- Five stocks we like better than Calithera Biosciences
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
